FDA U-turns sow uncertainty, create mixed messaging in rare diseases

In at least six cases since May, biopharma companies say FDA has shifted goalposts weeks or months before anticipated approvals, putting the future of drugs and companies in doubt.

Representatives of other companies have recently expressed similar concerns to BioCentury about abrupt shifts in regulatory expectations during clinical development. They declined to be identified to avoid disrupting ongoing discussions with the agency. ...